SC
SGMT icon

SummitTX Capital’s Sagimet Biosciences SGMT Stock Holding History

SummitTX Capital’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$176K Buy
+22,712
New +$154K ﹤0.01% 720

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

SummitTX Capital's SGMT Position: Q2 2026 in Review

SummitTX Capital opened a new position in Sagimet Biosciences (SGMT) in Q2 2026: 22,712 shares worth $176K. The stake represents ﹤0.01% of the portfolio and ranks #720 among its holdings.

122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • SummitTX Capital held 22,712 shares of Sagimet Biosciences worth $176K as of Q2 2026.
  • Sagimet Biosciences was a new SummitTX Capital position in Q2 2026.
  • Sagimet Biosciences made up ﹤0.01% of SummitTX Capital's portfolio in Q2 2026, its #720 holding.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.